Oryzon Genomics SA (ORYZF)
3.31
0.00 (0.00%)
USD |
OTCM |
Sep 24, 16:00
Oryzon Genomics Research and Development Expense (Annual) : 14.22M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 14.22M |
| December 31, 2024 | 9.135M |
| December 31, 2023 | 16.27M |
| December 31, 2022 | 17.79M |
| December 31, 2021 | 1.701M |
| December 31, 2020 | 1.353M |
| Date | Value |
|---|---|
| December 31, 2019 | 1.170M |
| December 31, 2018 | 8.747M |
| December 31, 2017 | |
| December 31, 2016 | 1.035M |
| December 31, 2015 | 4.113M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Pharma Mar SA | 104.94M |
| Grifols SA | 420.96M |
| ACADIA Pharmaceuticals, Inc. | 328.80M |
| Alkermes Plc | 318.36M |
| Alnylam Pharmaceuticals, Inc. | 1.320B |